featured
Long-Term Safety and Efficacy of Evolocumab in Paediatric Patients With Heterozygous Familial Hypercholesterolaemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT
Lancet Diabetes Endocrinol 2022 Sep 05;[EPub Ahead of Print], RD Santos, A Ruzza, GK Hovingh, C Stefanutti, F Mach, OS Descamps, J Bergeron, B Wang, A Bartuli, PS Buonuomo, S Greber-Platzer, I Luirink, AK Bhatia, FJ Raal, JJP Kastelein, A Wiegman, D GaudetFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.